<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257399</url>
  </required_header>
  <id_info>
    <org_study_id>03010302A</org_study_id>
    <secondary_id>2007L03525</secondary_id>
    <nct_id>NCT01257399</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase</brief_title>
  <official_title>Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tillotts Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tillotts Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that import Mesalazine (ASACOL速) is non-inferior to the reference drug,
      marketed Mesalazine, regarding the primary endpoint (rate of non-emergence of bloody stool),
      in patients with Ulcerative Colitis in remission, treated for 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of non-emergence of bloody stool</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Period of non-emergence of bloody stool, 2) Rate of non-recurrence, 3) Period of non-recurrence, 4) Reduction of UC-DAI score</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Ulcerative Colitis in Remission</condition>
  <arm_group>
    <arm_group_label>Asacol速</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Import Mesalazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesalazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed Mesalazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol速</intervention_name>
    <description>400 mg tablets</description>
    <arm_group_label>Asacol速</arm_group_label>
    <other_name>Import Mesalazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalazine</intervention_name>
    <description>400mg tablets</description>
    <arm_group_label>Mesalazine</arm_group_label>
    <other_name>Marketed Mesalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ulcerative colitis in remission who are defined to show an Ulcerative
             Colitis-Disease Activity Index (UC-DAI) score of 2 or less and a bloody stool score of
             0.

        Exclusion Criteria:

          -  Patients who take adrenal corticosteroid (oral formulation, enemas, suppository,
             agents for hemorrhoidal disease, injectable solution) within 14 days before start of
             administration of clinical study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

